http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASH
-
Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer
-
AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
-
Glenview Capital Enters Comcast (CMCSA), CVS (CVS), Twitter (TWTR) (more...) - 13F
-
AbbVie to Present at the Jefferies 2017 London Healthcare Conference
-
AbbVie (ABBV) Announces Positive Phase 3 Extension Study Data for Elagolix for Management of Endometriosis with Associated Pain
-
AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
-
AbbVie Reports Third-Quarter 2017 Financial Results
-
AbbVie Increases Quarterly Dividend by 11 Percent
-
AbbVie (ABBV) Announces FDA Priority Review for Elagolix for Management of Endometriosis with Associated Pain
-
AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
-
AbbVie (ABBV) Says Risankizumab Met All Co-Primary and Ranked Secondary Endpoints in Three Pivotal Phase 3 Psoriasis Studies
-
Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies
-
Dow, S&P gain but Nasdaq dips as healthcare lags
-
DDF notes major collaboration between portfolio company Alector and AbbVie to advance novel class of immune therapies for patients with Alzheimer's disease
-
AbbVie (ABBV) to Showcase Immunology Portfolio with New and Late-Breaking Data at ACR/ARHP
-
AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting
-
AbbVie (ABBV) and Alector Announce Pact to Advance Novel Class of Immune Therapies for Patients with AD
-
Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease
-
AbbVie (ABBV) and Harpoon Therapeutics Enter Immuno-Oncology Research Collaboration
-
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
-
AbbVie to Present at the 2017 Credit Suisse Health Care Conference
-
AbbVie (ABBV) Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at AASLD
-
AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
-
AbbVie (ABBV), Turnstone Biologics Announce Pact on Viral Immunotherapies in Oncology
-
AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology
-
AbbVie to Host Third-Quarter 2017 Earnings Conference Call
-
AbbVie (ABBV) Reports Resolution of HUMIRA Patent Disputes with Amgen (AMGN)
-
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen
-
AbbVie (ABBV) Reports Approval of MAVIRET (glecaprevir/pibrentasvir) in Japan
-
AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
-
AbbVie (ABBV), Bristol-Myers Squibb (BMY) Announce Pact to Evaluate Therapeutic Regimen in Advanced Solid Tumors
-
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
-
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
-
AbbVie (ABBV) Phase 3 MURANO Study of VENCLEXTA Met Primary Endpoint
-
AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Rela
-
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
-
AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis
-
AbbVie Declares Quarterly Dividend
-
AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year
-
AbbVie (ABBV) Says Upadacitinib Met Primary Endpoint in Phase 2b Study in Atopic Dermatitis
-
AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
-
AbbVie to Present at the Morgan Stanley 15th Annual Global Health Care Conference
-
AbbVie (ABBV) Submits NDA to FDA for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
-
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
-
AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
-
Johnson & Johnson (JNJ) Announces FDA Approval for IMBRUVICA in Adults with cGVHD
-
AbbVie (ABBV) Annouces FDA Approval of IMBRUVICA for Adults with cGVHD
-
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition -- Aft
-
European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
